Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyBryte PK and ECG Study in CTCL
NCT05380635Phase 2Completed
- Sponsor
- Soligenix
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of hypericin in cutaneous T-cell lymphoma (CTCL), sponsored by Soligenix. Started May 2022; status: completed.
02
Drugs
hypericin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05380635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380635.